Previous 10 | Next 10 |
Equillium press release ( NASDAQ: EQ ): Q3 GAAP EPS of -$0.40 misses by $0.02 . Cash, cash equivalents and short-term investments totaled $44.5 million as of September 30, 2022, compared to $57.6 million as of June 30, 2022. Equillium believes that its cash and investm...
Announced positive interim results from the EQUALISE study of itolizumab in highly proteinuric lupus nephritis patients: by week 28, 83% achieved complete or partial response, and 67% achieved > 80% reduction in urine protein creatinine ratio Announced the pending acquisiti...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that a poster presentation was given over the weekend at ACR Convergence, the...
Phase 2 proof-of-concept study evaluating EQ101 efficacy, safety, tolerability and PK/PD in subjects with alopecia areata over 24 weeks of treatment EQ101 targets IL-2, IL-9, and IL-15, key cytokines known to be upregulated in alopecia areata, and therefore may provide a more ...
Preclinical and translational data supports EQ101 for the treatment of alopecia areata Multi-Cytokine Inhibitors may provide a more selective and potent approach to treatment than direct JAK inhibition A phase 2 study of EQ101 in patients with alopecia areata to be...
Phase 1 study evaluating safety, tolerability and PK/PD after single and multiple ascending doses in healthy volunteers and biological activity in subjects with celiac disease Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel th...
Summary Today, we circle back on Equillium for the first time in a year and a half. The company has several compounds in development, recently disclosed encouraging trial results and also executed a small strategic merger. An investment analysis follows in the paragraphs below...
Results demonstrate the use of selective inhibitors of multiple key cytokines as an effective strategy in treating autoimmune diseases driven by T and NK cells Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to tr...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data regarding itolizumab....
Equillium, Inc. ( NASDAQ: EQ ), a biotech focused on immuno-inflammatory disorders, added ~22% i n the morning hours Tuesday as Street reacted to the company’s interim results from the Type B portion of the EQUALISE study evaluating its lead asset itolizumab in lupus ...
News, Short Squeeze, Breakout and More Instantly...
Q2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutic...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...